CFTR and cystic fibrosis: An interesting proof-of-concept study of the intranasal DOTAP liposomes targeting the CFTR gene that overexpressed in lung parenchyma of cystic fibrosis (CF) patients demonstrated the safety in the first-in-human trial application (109).